Haemonetics (HAE) Cash from Financing Activities (2009 - 2026)

Haemonetics' Cash from Financing Activities history runs 18 years deep, the most recent figure standing at -$101.5 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 32.98% year-over-year to -$101.5 million in Q1 2026; TTM through Mar 2026 was -$178.5 million, a 264.0% decrease from a year earlier, with the FY2026 full-year figure at -$178.5 million, down 264.0% from the prior year.
• Cash from Financing Activities eased to -$101.5 million in Q1 2026 per HAE's latest filing, from $2.0 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $333.7 million in Q2 2024 and bottomed at -$151.4 million in Q1 2025.
• The 5-year median for Cash from Financing Activities is -$8.0 million (2022), against an average of -$7.9 million.
• Biggest YoY gain for Cash from Financing Activities was 55901.34% in 2024; the steepest drop was 3861.45% in 2024.
• Year by year, Cash from Financing Activities stood at -$49.7 million in 2022, then surged by 320.27% to $109.4 million in 2023, then slumped by 98.74% to $1.4 million in 2024, then jumped by 47.32% to $2.0 million in 2025, then sank by 5092.57% to -$101.5 million in 2026.
• Per Business Quant, the three latest HAE Cash from Financing Activities figures stand at -$101.5 million (Q1 2026), $2.0 million (Q4 2025), and -$76.6 million (Q3 2025).